Epigenetic Reprogramming in Cadmium-Associated Liver Injury: Evidence, Mechanistic Insights, and Therapeutic Perspectives.

Authors

Xing Zhang, Na Liu, Jie Zhou

Published in

Environmental toxicology and pharmacology. Pages 105178. Sep 26, 2026. Epub Sep 26, 2026.

Abstract

Chronic cadmium (Cd) exposure is associated with adverse liver outcomes, including metabolic dysfunction-associated steatotic liver disease (MASLD), inflammation, and fibrosis, yet the mechanisms underlying persistent hepatic injury remain incompletely resolved. This review critically examines population-based and experimental evidence for Cd-associated epigenetic alterations, focusing on DNA methylation, histone modifications, N⁶-methyladenosine (m⁶A) RNA modification, and non-coding RNA regulation, and evaluates the extent to which these changes represent epigenetic dysregulation or remodeling versus relatively durable and functionally consequential reprogramming. Evidence is interpreted according to study design and level of functional validation. Current findings support context-dependent, model-specific roles for selected epigenetic regulators, with functional convergence on metabolic dysfunction, oxidative stress, inflammation, cell-death pathways, and fibrogenic activation, rather than a unified causal epigenetic program in humans. We further discuss cross-layer interactions, cell-type heterogeneity, emerging preclinical intervention strategies, and translational barriers, highlighting the need for longitudinal human studies, cell-resolved multi-omics, and target-specific functional validation.

PMID:
42800692
Bibliographic data and abstract were imported from PubMed on 27 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.